(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 17 July 2003 (17.07.2003)

PCT

(10) International Publication Number WO 03/057729 A3

- C07K 14/575. (51) International Patent Classification7: A61K 38/22, C12N 1/21, A01K 67/00
- PCT/EP03/00448 (21) International Application Number:
- (22) International Filing Date: 8 January 2003 (08.01.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

02290030.2

8 January 2002 (08.01.2002)

- (71) Applicant (for all designated States except US): IN-STITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM [FR/FR]; 101, rue de Tolbiac, F-75013 PARIS (FR).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): GOFFIN, Vincent [BE/FR]; 2, impasse des Chèvrefeuilles, F-78910 ORGERUS (FR). BERNICHTEIN, Sophie [FR/FR]; 61, rue des Ecoles, F-93300 AUBERVILLIERS (FR). KELLY, Paul, A. [FR/FR]; 54, rue Notre Dame de Lorette, F-75009 PARIS (FR).

- (74) Agents: VIALLE-PRESLES, Marie José et al.; CAB-INET ORES, 36, rue de St-Pétersbourg, F-75008 PARIS (FR).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- (88) Date of publication of the international search report: 16 October 2003

[Continued on next page]

(54) Title: MAMMAL PROLACTIN VARIANTS

hormones

8 C 1101	mones	1 9	Helix 1
h	PRL	LPICPGGAAR	COVTLRDLFDRAVVLSHYIHNLSSEMFS
h	GH	F	PTIPLSRLFDNAMLRAHRLHQLAFDTYQ
hPRL 1	mutants		
Δ:	1-9-hPRL	¹⁰ R	$\underline{\mathtt{SQVTLRDLFDRAVVLSHYIHNLSSEMFS}}$
٨١	L-10-hPRL	1	¹ SQVTLRDLFDRAVVLSHYIHNLSSEMFS
			12QVTLRDLFDRAVVLSHYIHNLSSEMFS
Δ.	L-11-hPRL		QVILRULFDRAVVLSHIIHNLSSEMFS
Δ1	L-12-hPRL		13VTLRDLFDRAVVLSHYIHNLSSEMFS
Δ1	l-13-hPRL		14TLRDLFDRAVVLSHYIHNLSSEMFS
Δ:	1-14-hPRL		15LRDLFDRAVVLSHYIHNLSSEMFS

(57) Abstract: The invention relates to mammal prolactin (PRL) variants having a mutation or set of mutations within the 14 N-terminal amino acids thereby preventing the formation of a disulfide bridge between Cys4 and Cys11 and, a sterically hindering mutation or set of mutations within binding site 2 of PRL. These variants are useful as antagonists of mammal prolactin receptors (PRLR), more particularly of human prolactin receptor (hPRLR).



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

INTERNATIONAL SEARCH REPORT

Interpopulation No PCT/EP 03/00448

A. CLASSII IPC 7	CO7K14/575 A61K38/22 C12N1/21	A01K67/00				
According to	International Patent Classification (IPC) or to both national classifica	ution and IPC				
B. FIELDS	SEARCHED					
Minimum documentation searched (classification system tollowed by dassification symbols) IPC 7 C07K A61K						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched						
	ata base consulted during the international search (name of data ba	se and, where practical, search terms used)				
EPO-Internal, BIOSIS						
C. DOCUME	ENTS CONSIDERED TO BE RELEVANT					
Category °	Citation of document, with indication, where appropriate, of the rel	evant passages Refevant to clatm No.				
Y	S. BERNICHTEIN ET AL.: "N-Termin Deletion in Human Prolactin Enhange Biological Activity and Reduces For Covalent Multimers" ENDO 2000, ENDOCRINE SOCIETY 82NE MEETING, TORONTO, June 2000 (2000-06), page 153 XFC cited in the application abstract 613 page 153	ormation ANNUAL				
X Funth	er documents are listed in the continuation of box C.	Patent family members are listed in annex.				
•	egortes of cited documents: nt defining the general state of the art which is not	"T' later document published after the international filing date or priority date and not in conflict with the application but				
consid	ered to be of particular relevance ocument but published on or after the international	cited to understand the principle or theory underlying the invention X' document of particular relevance; the claimed invention				
"L" documer	nt which may throw doubts on priority claim(s) or	cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone				
which is cited to establish the publication date of enother citation or other special reason (as specified) "Y" document of particular relevance; the cialmed invention cannot be considered to involve an inventive step when the						
other n	nt published prior to the international filling date but	document is combined with one or more other such docu- ments, such combination being obvious to a person skilled in the art. *&* document member of the same patent family				
	actual completion of the international search	Date of mailing of the international search report				
	June 2003	15/07/2003				
Name and m	alling address of the ISA	Authorized officer				
	European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3016	Stolz, B				

INTERNATIONAL SEARCH REPORT

Intermonal Application No PCT/EP 03/00448

		PCT/EP 03/00448	
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with Indication where appropriate, of the relevant passages	Relevant to claim No.	
Y	V. GOFFIN ET AL.: "Antagonistic Properties of Human Prolactin Analogs That Show Paradoxical Agonistic Activity in the Nb2 Bioassay" J. BIOL. CHEM., vol. 271, no. 28, 12 July 1996 (1996-07-12), pages 16573-16579, XP002921797 cited in the application Discussion	1-12	
A .	M. LLOVERA ET AL.: "Involvement of prolactin in breast cancer: redefining the molecular targets" EXPERIMENTAL GERONTOLOGY, vol. 35, 2000, pages 41-51, XP002198974 page 48, paragraph 2		
A	A. TCHELET ET AL.: "Selective Modification at the N-terminal Region of Human Growth Hormone That Shows Antagonistic Activity" MOLECULAR AND CELLULAR ENDOCRINOLOGY, vol. 130, 1997, pages 141-152, XP002198975 abstract		